Abstract
There is no clear consensus regarding the most effective management of poor responders to neoadjuvant chemotherapy. Intensifying or changing primary systemic treatment has not been shown to offer any benefit. There is a paucity of trials testing the utility of adjuvant chemotherapy in this setting. Adjuvant hormonal treatment significantly decreases relapse rates in patients with estrogen receptor-positive breast cancer, regardless of initial response to chemotherapy. Neoadjuvant hormonal therapy is usually reserved for patients who are not candidates for chemotherapy or surgery. In patients with HER-2-overexpressing tumors who are candidates for chemotherapy, trastuzumab improves outcomes when administered in the preoperative or postoperative setting. This article examines issues related to the assessment of response to preoperative therapy and the clinical use of these assessments. It reviews important clinical evidence related to the utility of further treatment in patients with breast cancer that has responded poorly to neoadjuvant treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
